Online inquiry

IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6507MR)

This product GTTS-WQ6507MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6507MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6799MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ6919MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ1099MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ11434MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ12871MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ144MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ6811MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ1597MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW